KR102799156B1 - Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 - Google Patents

Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 Download PDF

Info

Publication number
KR102799156B1
KR102799156B1 KR1020207033073A KR20207033073A KR102799156B1 KR 102799156 B1 KR102799156 B1 KR 102799156B1 KR 1020207033073 A KR1020207033073 A KR 1020207033073A KR 20207033073 A KR20207033073 A KR 20207033073A KR 102799156 B1 KR102799156 B1 KR 102799156B1
Authority
KR
South Korea
Prior art keywords
delete delete
pain
epilepsy
tpa023b
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207033073A
Other languages
English (en)
Korean (ko)
Other versions
KR20210011921A (ko
Inventor
매튜 토츠코
제드 허브스
Original Assignee
뉴로사이클 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로사이클 테라퓨틱스, 인크. filed Critical 뉴로사이클 테라퓨틱스, 인크.
Priority to KR1020257012376A priority Critical patent/KR20250057112A/ko
Publication of KR20210011921A publication Critical patent/KR20210011921A/ko
Application granted granted Critical
Publication of KR102799156B1 publication Critical patent/KR102799156B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Psychiatry (AREA)
KR1020207033073A 2018-04-18 2019-04-17 Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 Active KR102799156B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257012376A KR20250057112A (ko) 2018-04-18 2019-04-17 Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659226P 2018-04-18 2018-04-18
US62/659,226 2018-04-18
PCT/US2019/027880 WO2019204446A1 (en) 2018-04-18 2019-04-17 Gabaa positive allosteric modulator compounds, methods of making, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257012376A Division KR20250057112A (ko) 2018-04-18 2019-04-17 Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도

Publications (2)

Publication Number Publication Date
KR20210011921A KR20210011921A (ko) 2021-02-02
KR102799156B1 true KR102799156B1 (ko) 2025-04-21

Family

ID=68239798

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207033073A Active KR102799156B1 (ko) 2018-04-18 2019-04-17 Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도
KR1020257012376A Pending KR20250057112A (ko) 2018-04-18 2019-04-17 Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257012376A Pending KR20250057112A (ko) 2018-04-18 2019-04-17 Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도

Country Status (14)

Country Link
US (3) US11542263B2 (https=)
EP (1) EP3781566A4 (https=)
JP (3) JP7449272B2 (https=)
KR (2) KR102799156B1 (https=)
CN (2) CN112384513A (https=)
AU (2) AU2019255282B2 (https=)
BR (1) BR112020021104A2 (https=)
CA (1) CA3096890A1 (https=)
CL (1) CL2020002663A1 (https=)
IL (1) IL278067A (https=)
MX (2) MX2020010878A (https=)
SG (1) SG11202010220QA (https=)
TW (1) TW202012402A (https=)
WO (1) WO2019204446A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7449272B2 (ja) * 2018-04-18 2024-03-13 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリックモジュレーター化合物、その作製の方法および使用
SG11202109526PA (en) * 2019-03-18 2021-10-28 Neurocycle Therapeutics Inc Use of gabaa receptor modulators for treatment of pain
JP2022553718A (ja) * 2019-10-22 2022-12-26 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリック調節因子化合物、作成方法、およびその使用
KR20220087507A (ko) * 2019-10-23 2022-06-24 뉴로사이클 테라퓨틱스, 인크. Gabaa 수용체 조절제를 사용한 간질 병태의 치료
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder
AU2023356939A1 (en) * 2022-10-04 2025-04-10 Engrail Therapeutics, Inc. Gaba a receptor modulators and uses thereof
WO2025175214A1 (en) * 2024-02-16 2025-08-21 Engrail Therapeutics, Inc. Methods of treating generalized anxiety disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536862A (ja) * 2001-07-16 2004-12-09 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体のためのリガンドとしてのイミダゾ−トリアジン誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2802343C2 (de) 1978-01-20 1982-04-22 Peter Prof. Dr.-Ing. Friderichs Latentwärmespeicher-Behälter
GB9813576D0 (en) * 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
CA2427779A1 (en) * 2000-11-10 2002-05-16 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
JP2004170323A (ja) 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
WO2009021957A2 (en) 2007-08-14 2009-02-19 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US20110082147A1 (en) 2009-07-24 2011-04-07 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
WO2015072853A1 (en) 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks
SG11201806393QA (en) * 2016-01-27 2018-08-30 Univ Zuerich Use of gabaa receptor modulators for treatment of itch
JP7449272B2 (ja) * 2018-04-18 2024-03-13 ニューロサイクル・セラピューティクス・インコーポレイテッド Ｇａｂａａ陽性アロステリックモジュレーター化合物、その作製の方法および使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536862A (ja) * 2001-07-16 2004-12-09 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体のためのリガンドとしてのイミダゾ−トリアジン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Org. Chem, Vol. 70, No. 15, 2005, 5938-5945.*

Also Published As

Publication number Publication date
JP7721712B2 (ja) 2025-08-12
AU2019255282B2 (en) 2024-08-08
WO2019204446A1 (en) 2019-10-24
SG11202010220QA (en) 2020-11-27
AU2019255282A1 (en) 2020-11-05
AU2024259803A1 (en) 2024-11-28
CN112384513A (zh) 2021-02-19
US20230139418A1 (en) 2023-05-04
EP3781566A4 (en) 2022-06-22
JP2025166011A (ja) 2025-11-05
JP2024063136A (ja) 2024-05-10
CN121135719A (zh) 2025-12-16
MX2024004400A (es) 2024-04-29
KR20210011921A (ko) 2021-02-02
KR20250057112A (ko) 2025-04-28
US20210040103A1 (en) 2021-02-11
JP7449272B2 (ja) 2024-03-13
US20250034155A1 (en) 2025-01-30
BR112020021104A2 (pt) 2021-02-23
JP2021522330A (ja) 2021-08-30
MX2020010878A (es) 2021-01-29
US12134619B2 (en) 2024-11-05
IL278067A (en) 2020-11-30
CA3096890A1 (en) 2019-10-24
TW202012402A (zh) 2020-04-01
CL2020002663A1 (es) 2021-06-11
EP3781566A1 (en) 2021-02-24
US11542263B2 (en) 2023-01-03

Similar Documents

Publication Publication Date Title
KR102799156B1 (ko) Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도
AU2020364142A1 (en) Solid state crystalline forms of a selective potassium channel modulator
JP2026021408A (ja) Ｇａｂａａ陽性アロステリック調節因子化合物、作成方法、およびその使用
EP2819998B1 (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1h-indazol-5-yloxy)benzyl)urea hydrochloride
JP2021512118A (ja) 医薬化合物、その塩、その製剤、ならびにそれらの作製および使用方法
WO2008111092A1 (en) Crystalline temozolomide monohydrate and process for preparation thereof
JP2018024636A (ja) ［（２ｒ，３ｓ，４ｒ，５ｒ）−５−（６−（シクロペンチルアミノ）−９ｈ−プリン−９−イル）−３，４−ジヒドロキシテトラヒドロフラン−２−イル］メチルナイトレートの無水多形体及びその製造方法
EP4660196A1 (en) Crystal form of compound, preparation method therefor and use thereof
US20230105181A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
HK40128637A (en) Crystal form of compound, preparation method therefor and use thereof
HK1204475B (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1h-indazol-5-yloxy)benzyl)urea hydrochloride

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220415

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240708

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250220

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250417

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250417

End annual number: 3

Start annual number: 1

PG1601 Publication of registration